Of the 14 patients with Ph−/BCR-ABL1 + CML, 12 (85.7%) had BCR-ABL1IS ≤1%, and 1 had BCR-ABL1IS >1 to ≤10% at 3 months. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.